HDAC8-IN-12, with the CAS number 3028095-13-5, is a chemical compound that functions as an inhibitor of histone deacetylase 8 (HDAC8), an enzyme involved in the regulation of gene expression through the modification of histones. This compound is characterized by its ability to selectively inhibit HDAC8, which plays a crucial role in various cellular processes, including cell differentiation, proliferation, and apoptosis. The inhibition of HDAC8 has implications in cancer therapy, as altered histone acetylation patterns can lead to tumorigenesis. HDAC8-IN-12 is typically studied in the context of its potential therapeutic applications, particularly in the treatment of certain cancers and neurodegenerative diseases. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for HDAC8. Research on this compound may also explore its pharmacokinetics, toxicity, and efficacy in biological systems, making it a subject of interest in medicinal chemistry and drug development.

HDAC8-IN-12

3028095-13-5: HDAC8-IN-12, with the CAS number 3028095-13-5, is a chemical compound that functions as an inhibitor of histone deacetylase 8 (HDAC8), an enzyme involved in the regulation of gene expression through the modification of histones. This compound is characterized by its ability to selectively inhibit HDAC8, which plays a crucial role in various cellular processes, including cell differentiation, proliferation, and apoptosis. The inhibition of HDAC8 has implications in cancer therapy, as altered histone acetylation patterns can lead to tumorigenesis. HDAC8-IN-12 is typically studied in the context of its potential therapeutic applications, particularly in the treatment of certain cancers and neurodegenerative diseases. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for HDAC8. Research on this compound may also explore its pharmacokinetics, toxicity, and efficacy in biological systems, making it a subject of interest in medicinal chemistry and drug development.

HDAC8-IN-12 (compound 5k), a non-hydroxamic acid derivative, serves as a selective HDAC8 inhibitor with an IC 50 of 0.12 nM and demonstrates potent efficacy against breast cancer. This compound enhances anti-tumor immunity by activating T cells, elevating M1 macrophage levels, and reducing M2 macrophage proportions. In an orthotopic mouse model of breast cancer, HDAC8-IN-12, administered at 50 mg/kg, effectively suppresses tumor growth.

CAS 3028095-13-5

HDAC8-IN-12

HDAC8-IN-12

Ref: TM-T200383